Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib

JAMA Dermatology

Volumn 149, Issue 3, 2013, Pages 322-326

  Falchook, Gerald S ^a,f   Rady, Peter ^d   Hymes, Sharon ^b   Nguyen, Harrison P ^e   Tyring, Stephen K ^d   Prieto, Victor G ^c   Hong, David S ^a   Kurzrock, Razelle ^a  

^a Department of Investigational Cancer Therapeutics ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e RICE UNIVERSITY   (United States)

^f Unit 455   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DIPHENHYDRAMINE; METHYLPREDNISOLONE; UREA; VIRUS DNA;

ACTINIC KERATOSIS; ADULT; ALPHAPAPILLOMAVIRUS; ARTICLE; BRAF GENE; CANCER SIZE; CASE REPORT; CHEMOSURGERY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CODON; CRYOTHERAPY; DISEASE ASSOCIATION; DRUG ERUPTION; DYSKERATOSIS; EPIDERMODYSPLASIA VERRUCIFORMIS; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 17; HUMAN TISSUE; INTRON; LUNG METASTASIS; MELANOMA; MERKEL CELL POLYOMAVIRUS; MULTIPLE CYCLE TREATMENT; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; PAPULE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SKIN BIOPSY; SKIN CARCINOMA; SKIN DEFECT; TREATMENT DURATION; VERRUCA VULGARIS; VIRUS DETECTION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMANS; IMIDAZOLES; MELANOMA; MERKEL CELL POLYOMAVIRUS; MIDDLE AGED; OXIMES; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS;

EID: 84875399925     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.2023     Document Type: Article

References (40)

1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
2. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901.
3. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
4. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3): 207-215.
5. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
6. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
7. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
8. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177-182.
9. Cichowski K, Jänne PA. Drug discovery: inhibitors that activate. Nature. 2010;464 (7287):358-359.
10. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-3044.
11. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10(3):803-821.
12. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-1100.
13. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol. 2009;27(24):4021-4026.
14. Dworkin AM, Tseng SY, Allain DC, Iwenofu OH, Peters SB, Toland AE. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol. 2009;129(12):2868-2874.
15. Murakami M, Imajoh M, Ikawa T, et al. Presence of Merkel cell polyomavirus in Japanese cutaneous squamous cell carcinoma. J Clin Virol. 2011;50(1):37-41.
16. Kassem A, Technau K, Kurz AK, et al. Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer. 2009;125(2):356-361.
17. Ridd K, Yu S, Bastian BC. The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol. 2009;129(1): 250-252.
18. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-1956.
19. Bosch FX, Manos MM, Muñoz N, et al; International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87(11):796-802.
20. Varma VA, Sanchez-Lanier M, Unger ER, et al. Association of human papillomavirus with penile carcinoma: a study using polymerase chain reaction and in situ hybridization. Hum Pathol. 1991;22(9):908-913.
21. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177 (2):361-367.
22. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst. 2006;98(6):389-395.
23. Yutsudo M, Shimakage T, Hakura A. Human papillomavirus type 17 DNA in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Virology. 1985;144(1):295-298.
24. Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and nonmelanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247-259.
25. Rollison DE, Pawlita M, Giuliano AR, et al. Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer. 2008;123(10):2337-2342.
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
27. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990;82(18):1477-1484.
28. Berkhout RJ, Tieben LM, Smits HL, Bavinck JN, Vermeer BJ, ter Schegget J. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol. 1995;33(3):690-695.
29. de Oliveira WR, He Q, Rady PL, et al. HPV typing in Brazilian patients with epidermodysplasia verruciformis: high prevalence of EV-HPV 25. J Cutan Med Surg. 2004;8(2):110-115.
30. Yutsudo M, Hakura A. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Int J Cancer. 1987;39(5):586-589.
31. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144(6):779-782.
32. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20-23.
33. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59-e61. doi:10.1200/JCO.2009.23.4823.
34. Rust A, McGovern RM, Gostout BS, Persing DH, Pittelkow MR. Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. J Am Acad Dermatol. 2001;44(4):681-686.
35. de Koning MN, Weissenborn SJ, Abeni D, et al; EPI-HPV-UV-CA group. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol. 2009;90(pt 7):1611-1621.
36. Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol. 2008;43(4): 353-360.
37. Foulongne V, Dereure O, Kluger N, Molès JP, Guillot B, Segondy M. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol. 2010;162(1): 59-63.
38. Karagas MR, Waterboer T, Li Z, et al; New Hampshire Skin Cancer Study Group. Genus β human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ. July 8, 2010;341:c2986. doi:10.1136/bmj.c2986.
39. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Paper presented at American Society of Clinical Oncology Meeting; June 4, 2011; Chicago, I.L.
40. Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS. Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol. 2010;63(3):400-403.